Ipidacrine Hydrochloride Grindeks

Ipidacrine, the active ingredient in Ipidacrine Hydrochloride, is an acetylcholinesterase inhibitor presented as a tablet for oral use. It is used to improve cognitive function in adults with cognitive impairment or dementia.

GNH USA supplies Ipidacrine Hydrochloride as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipidacrine acts on the cholinergic system to address disorders of cognition. It is indicated for several recognized conditions: - Cognitive impairment: helps improve memory, attention and overall mental performance. - Dementia: supports cognitive function and may slow symptom progression. - Age‑related cognitive decline: may aid in maintaining mental acuity in older adults.

Ipidacrine may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: transient light‑headedness. - Headache: occasional tension‑type pain. - Gastrointestinal discomfort: abdominal cramping or diarrhea. - Fatigue: feeling unusually tired. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Cardiac arrhythmia: irregular heartbeat. - Seizures: convulsive episodes. - Allergic reactions: rash, swelling, anaphylaxis. - Blood dyscrasias: neutropenia or thrombocytopenia. - Persistent vomiting: may lead to dehydration.

Before initiating therapy, consider the following safety measures: - Renal impairment: adjust use in patients with reduced kidney function. - Hepatic impairment: monitor liver enzymes regularly. - Elderly patients: start at the lowest effective dose and watch for confusion. - Concomitant cholinergic drugs: avoid additive cholinergic effects. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Ipidacrine can interact with several medication classes. Review patient medication lists carefully.

Major Interactions (Avoid): - Other acetylcholinesterase inhibitors: risk of excessive cholinergic activity. - Anticholinergic agents: may counteract therapeutic effect. - Certain antiarrhythmic drugs: potential for cardiac conduction disturbances.

Moderate Interactions (Monitor Closely): - Central nervous system depressants: may enhance sedation. - Antihypertensive agents: possible additive blood pressure lowering. - Anticoagulants: monitor for altered bleeding risk.